Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

Not Applicable

Completed

• Conditions: Diabetes Mellitus

• Registration Number: NCT00334711
• Lead Sponsor: Royal Devon and Exeter NHS Foundation Trust

Brief Summary

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Study Completion: 2006-01
• Status Verified: 2006-06
• Study First Submitted: 2006-06-07
• Study First Submitted QC: 2006-06-07
• Study First Posted: 2006-06-08
• Last Update Submitted: 2006-11-28
• Last Update Posted: 2006-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Diabetes due to KCNJ11 (Kir6.2) mutation

Exclusion Criteria

• None

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
HbA1c reduction

Secondary Outcome Measures

Name	Time	Method
insulin secretory response to intravenous glucose
insulin secretory response to oral glucose
insulin secretory response to mixed meal (sustacal)
Incidence of Hypoglycemia